GSE168523
PPARd inhibition blocks tumor-induced Bregs and enhances CD40 agonist immunotherapy
Most cancers are cold tumors characterized by a lack of effector T cells and hence unresponsive to immune checkpoint blockades, highlighting the importance of repairing the failed T cell priming in cancer immunotherapy. CD40 agonists are efficient in eliciting T cell responses and effective in converting cold tumors into hot, their clinical application, however, is limited by the very narrow window between the effective and toxic dosages. Here, we sought to reduce the effective dosage of CD40 agonists by combination therapy. We identified a CD19+CD24hiCD38lowIgDlow/- regulatory B cell (Breg) subset that is increased in tumor-bearing mice and cancer patients, and discovered that PPARd is highly expressed in these tumor-associated Bregs and required for their proliferation and function. Inhibition of PPARd acted synergistically with agonist anti-CD40 to enhance antitumor immunity without increasing toxicity in murine melanoma and bladder carcinoma models. Combination therapy with PPARd inhibitor could reduce anti-CD40 dosage by over 60% to a well-tolerated level with improved or at least not compromised antitumor effects, providing a potential strategy for safely using CD40 agonists in cancer treatment. PPARd also offers a new target for selectively blocking Breg activity while sparing immunostimulatory B cells that are known to aid antitumor immunotherapy. Overall design: C57BL/6 mice were inoculated s.c. with 7 × 105 B16 cells and treated 8 days later by FGK45.5 or Rat IgG (peritumorally s.c.; 25 µg × 3 at day 8, 11 and 14), or GSK3787 (300 nmol; daily from day 8 to day 16), or FGK45.5 plus GSK3787. Cells of draining lymph nodes were prepared from these tumor-bearing mice at day 17 and age-matched naïve mice (n=3/group), and CD19+ B cells were sorted from pooled draining lymph nodes and analyzed for whole-transcriptome profiling by RNA-seq.